Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device

By LabMedica International staff writers
Posted on 03 Dec 2025

Routine blood tests remain dependent on off-site laboratories, resulting in delays, higher costs, and logistical barriers in decentralized care settings. More...

Now, a new multimodal diagnostic solution delivers lab-quality results from a small blood sample in minutes, simplifying workflows and expanding access to timely testing.

Truvian Health (San Diego, CA, USA) has developed the TruVerus benchtop analyzer that is capable of running clinical chemistries, immunoassays, and hematology assays on a single platform. Until now, no single on-site platform could run clinical chemistry, immunoassays, and hematology in a single device. By uniting three major testing modalities in one device, TruVerus represents a significant shift toward decentralized diagnostics.

TruVerus integrates patented technologies and proprietary dry-reagent architecture to deliver comprehensive results from a fraction of the blood required by traditional testing. The compact, plug-and-play instrument provides automated, lab-accurate results within minutes and is designed to eliminate send-outs while reducing the complexity of routine diagnostics.

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for TruVerus. The system’s initial clearance includes a kidney health panel measuring creatinine, blood urea nitrogen (BUN), and eGFR. Each test run uses a disposable disc and a support pack that contains all necessary reagents for multimodal analysis. Additional assay panels have already been submitted for FDA review as part of the company’s staged-clearance strategy to build a full menu of routine blood tests on a single, automated benchtop platform.

“Truvian is poised to disrupt the diagnostics industry by creating a future where full lab testing is decentralized, improving access, and providing results in minutes, while using only a fraction of the blood needed for other routine blood testing,” said Michael J. Mina, MD, Ph.D., one of the leading diagnostics and industry experts and member of Truvian’s scientific advisory board. “This boldly empowers providers to deliver faster, more informed, and ultimately, more equitable care.”

Related Link
Truvian Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.